Clinical decision on a patient with ALK+diffuse large B cell lymphoma / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 385-391, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-494347
ABSTRACT
Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regi-men is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This arti-cle presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibi-tor Crizotinib.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Chinese Journal of Clinical Oncology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS